BioCentury | Jun 16, 2020
Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

RA Capital to fund Novavax  Novavax Inc. (NASDAQ:NVAX) said Monday it will raise $200 million through a private placement of 4.4 million shares at $45.57, its closing price on Friday, to RA Capital Management. The...
BC Innovations | Oct 4, 2019
Emerging Company Profile

Arcellx debuts with $85M, tech for adapting CAR Ts

Arcellx emerged from stealth with over $85 million in series B funding and a team of CAR T veterans to develop the latest iteration of a CAR T adaptor platform that balances safety and efficacy...
BioCentury | Apr 18, 2019
Finance

Arranging Arrakis' syndicate

As it raised a $75 million series B round that will help its early research coalesce into a preclinical pipeline, Arrakis sought an investor syndicate that would build its expertise as it seeks to become...
BC Extra | Dec 20, 2018
Politics & Policy

FDA releases next guidance in patient-focused drug development series

FDA released draft guidance on Thursday to encourage industry and other stakeholders to submit proposed draft guidances for incorporating patient experience data into product development and regulatory decisions. The agency said stakeholders could submit their...
BioCentury | Sep 21, 2018
Product Development

Arrowhead refills its quiver

Arrowhead Pharmaceuticals Inc.’s tox blowup in 2016 set back its clinical timelines, but it also prompted the company to bring a more versatile platform online faster than originally planned. Early data from replacement candidates suggest...
BioCentury | Dec 23, 2017
Regulation

Prioritizing preferences

The realization that patients have distinct preferences about the trade-offs and risks inherent in medical decisions -- and that their choices are frequently different from those physicians or regulators would make -- has mobilized FDA,...
BC Innovations | Oct 12, 2017
Targets & Mechanisms

Mining the negatives

By investigating why its discontinued siRNA candidate against hepatitis B caused only weak responses in certain patients, Arrowhead Pharmaceuticals Inc. has upended a dogma about the virus’ genetics that has been clouding drug design and...
BC Innovations | Aug 31, 2017
Translation in Brief

Extinguishing aversion

Last month in the Journal of Neuroscience , a team from the Chinese Academy of Sciences showed activating RAC1 could help treat opioid addiction by extinguishing the aversive memories of withdrawal that cause relapse in some...
BC Innovations | Feb 9, 2017
Finance

PPP decline

BioCentury’s sixth annual analysis of public-private partnerships (PPPs) shows the lowest number of new alliances in 2016 since tracking began. The decline is a stark contrast to the enthusiasm of 2012, suggesting partners are becoming...
BC Week In Review | Jan 20, 2017
Company News

Heat, Shattuck deal

Heat granted newco Shattuck an exclusive license to Heat technology, which Shattuck will use to develop its agonist redirected checkpoint (ARC) platform technology. The technology blocks checkpoint molecules and stimulates tumor necrosis factor (TNF) superfamily...
Items per page:
1 - 10 of 71